Ignite Creation Date:
2024-05-06 @ 10:14 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03202667
Status:
COMPLETED
Last Update Posted:
2021-12-13
First Post:
2017-06-27
Brief Title:
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Sponsor:
University Hospital Basel Switzerland
Organization:
University Hospital Basel Switzerland
Study Overview
Official Title:
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Status:
COMPLETED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SANDx
Brief Summary:
Syndrome of inappropriate antidiuresis SIADH is characterized by an imbalance of antidiuretic vasopressin AVP secretion The impaired AVP regulation leads to water retention and secondary natriuresis and is a common cause for hyponatremia
Especially chronic 72h SIADH is difficult to treat as standard therapeutic options water restriction urea salt tablets often do not succeed in correction of hyponatremia making additional therapy necessary
Empagliflozin is a sodium glucose co-transporter 2 SGLT2-inhibitor which is a well-tolerated treatment option for type 2 diabetes mellitus The inhibition of SGLT2 in the proximal tubule leads to renal excretion of glucose with subsequent osmotic diuresis This mechanism could result in a therapeutic effect in patients with chronic SIADH as it resembles the aquaretic effect of urea
The aim of this study is to evaluate whether empagliflozin has an effect on the serum sodium levels of patients with chronic SIADH
Especially chronic 72h SIADH is difficult to treat as standard therapeutic options water restriction urea salt tablets often do not succeed in correction of hyponatremia making additional therapy necessary
Empagliflozin is a sodium glucose co-transporter 2 SGLT2-inhibitor which is a well-tolerated treatment option for type 2 diabetes mellitus The inhibition of SGLT2 in the proximal tubule leads to renal excretion of glucose with subsequent osmotic diuresis This mechanism could result in a therapeutic effect in patients with chronic SIADH as it resembles the aquaretic effect of urea
The aim of this study is to evaluate whether empagliflozin has an effect on the serum sodium levels of patients with chronic SIADH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None